Section Arrow
Quote
MDGL.NASDAQ
- Madrigal Pharmaceuticals
Quotes are at least 15-min delayed:2026/01/07 13:13 EST
Regular Hours
Last
 562.18
+4.17 (+0.75%)
Day High 
578.08 
Prev. Close
558.01 
1-M High
615 
Volume 
145.35K 
Bid
560.5
Ask
562.18
Day Low
558.63 
Open
560.87 
1-M Low
532.445 
Market Cap 
12.67B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 590.26 
20-SMA 575.85 
50-SMA 540.5 
52-W High 615 
52-W Low 265 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.91/15.19
Enterprise Value
12.79B
Balance Sheet
Book Value Per Share
27.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
180.13M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1276+0.0226+21.52%-- 
VTYXVentyx Biosciences13.7609+3.7109+36.92%-- 
RXRXRecursion Pharmaceuticals4.8499+0.2999+6.59%-- 
GLUEMonte Rosa Therapeutics23.75+7.74+48.34%54.09PE
MREOMereo BioPharma Group plc0.3946+0.0156+4.12%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.